Synopsis
Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cp 690,550
2. Cp 690550
3. Cp-690,550
4. Cp-690550
5. Cp690550
6. Tasocitinib
7. Tofacitinib
8. Xeljanz
1. 540737-29-9
2. Tasocitinib Citrate
3. Xeljanz
4. Cp-690550 Citrate
5. Tofacitinib (citrate)
6. Tofacitinib (cp-690550) Citrate
7. Xeljanz Xr
8. Tofacitinib Citrate [usan]
9. Cp-690,550-10
10. Tasocitinib Monocitrate
11. 540737-29-9 (citrate)
12. Cp-690550-10
13. Cp 690550 Citrate
14. O1ff4div0d
15. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate
16. Chebi:71197
17. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)- Beta-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
18. 2-hydroxypropane-1,2,3-tricarboxylic Acid; 3-[(3r,4r)-4-methyl-3-[methyl({7h-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile
19. 2-hydroxypropane-1,2,3-tricarboxylic Acid;3-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
20. Unii-o1ff4div0d
21. Mfcd11616529
22. 3-{(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate
23. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Citrate Salt
24. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl}-amino]-piperidin-1-yl)-3-oxo-propionitrile Citrate Salt
25. Xeljanz (tn)
26. Tofacitinib Monocitrate
27. Tasocitinib Citric Acid Salt
28. Cep-18770(delanzomib)
29. Mls006010058
30. Schembl1374185
31. Chembl2103743
32. Tofacitinib Citrate (jan/usan)
33. Amy4175
34. Dtxsid80202404
35. Ex-a204
36. Tofacitinib Citrate [jan]
37. C16h20n6o.c6h8o7
38. Tofacitinib Monocitrate [mi]
39. Hy-40354a
40. S5001
41. Tofacitinib Citrate [who-dd]
42. Akos022178222
43. Cp-690550 - Tofacitinib Citrate
44. Tofacitinib Citrate, >=98% (hplc)
45. Ccg-269730
46. Cs-0928
47. Tofacitinib Citrate [orange Book]
48. Ac-25004
49. As-19392
50. Bt163661
51. Smr004701220
52. Cp-690550 Citrate (tofacitinib Citrate)
53. Tofacitinib Citrate (cp-690550 Citrate)
54. Cp 690550-10
55. D09783
56. Q27139435
57. (3r,4r)-4-methyl-3-(methyl-7h-pyrro Lo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepro Panenitrile Citrate
58. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-?-oxo-1-piperidinepropanenitrile Citrate
59. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine Propanenitrile 2-hydroxy-1,2,3-propanetricarboxylate
60. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-ss-oxo-1-piperidinepropanenitrile Citrate Salt
61. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-.beta.-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
62. 1-piperidinepropanenitrile,4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-,(3r,4r)-,2-hydroxy-1,2,3-propanetricarboxylate(1:1)
63. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxo-propanenitrile2-hydroxypropane-1,2,3-tricarboxylate (1:1)
64. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile Mono Citrate Salt
65. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Mono Citrate Salt
Molecular Weight | 504.5 g/mol |
---|---|
Molecular Formula | C22H28N6O8 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 8 |
Exact Mass | 504.19686187 g/mol |
Monoisotopic Mass | 504.19686187 g/mol |
Topological Polar Surface Area | 221 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 716 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Xeljanz |
PubMed Health | Tofacitinib (By mouth) |
Drug Classes | Antirheumatic, Musculoskeletal Agent |
Drug Label | XELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy... |
Active Ingredient | Tofacitinib citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 5mg base |
Market Status | Prescription |
Company | Pf Prism Cv |
2 of 2 | |
---|---|
Drug Name | Xeljanz |
PubMed Health | Tofacitinib (By mouth) |
Drug Classes | Antirheumatic, Musculoskeletal Agent |
Drug Label | XELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy... |
Active Ingredient | Tofacitinib citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 5mg base |
Market Status | Prescription |
Company | Pf Prism Cv |
Janus Kinase Inhibitors
Agents that inhibit JANUS KINASES. (See all compounds classified as Janus Kinase Inhibitors.)
Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33332
Submission : 2018-12-21
Status : Active
Type : II
NDC Package Code : 11712-895
Start Marketing Date : 2021-02-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35976
Submission : 2021-05-29
Status : Active
Type : II
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-036
Start Marketing Date : 2021-05-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-12-20
Pay. Date : 2023-11-15
DMF Number : 37164
Submission : 2022-07-29
Status : Active
Type : II
NDC Package Code : 71796-050
Start Marketing Date : 2022-07-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37532
Submission : 2022-10-28
Status : Active
Type : II
NDC Package Code : 52076-6267
Start Marketing Date : 2020-12-08
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-03-06
Pay. Date : 2024-01-31
DMF Number : 38994
Submission : 2023-12-02
Status : Active
Type : II
NDC Package Code : 42765-036
Start Marketing Date : 2021-05-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33332
Submission : 2018-12-21
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35976
Submission : 2021-05-29
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : Complete
Rev. Date : 2024-03-06
Pay. Date : 2024-01-31
DMF Number : 38994
Submission : 2023-12-02
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2023-12-20
Pay. Date : 2023-11-15
DMF Number : 37164
Submission : 2022-07-29
Status : Active
Type : II
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37532
Submission : 2022-10-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-05-08
Pay. Date : 2015-03-10
DMF Number : 29002
Submission : 2015-03-11
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-11-13
Pay. Date : 2015-09-23
DMF Number : 27721
Submission : 2013-11-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-10-21
Pay. Date : 2016-06-22
DMF Number : 30578
Submission : 2016-06-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30554
Submission : 2016-05-19
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-09-28
Pay. Date : 2016-07-14
DMF Number : 30617
Submission : 2016-08-02
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Capsule
Grade : Parenteral, Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Dosage Form : Softgels
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?